Brian Lestini News Today

-BHV-1510 is a novel trophoblast cell surface antigen-2 (Trop-2) directed antibody drug conjugate (ADC) that has demonstrated a highly differentiated...

-BHV-1510 is a novel trophoblast cell surface antigen-2 (Trop-2) directed antibody drug conjugate (ADC) that has demonstrated a highly differentiate

/PRNewswire/ -- Pyramid Biosciences, Inc., a privately-held, clinical-stage biotechnology company focused on developing transformative medicines for patients...

PBI-200 is being developed for the treatment of NRTK fusion-positive solid tumors, including primary and metastatic brain tumorsPBI-200 is presently being evaluated in a global Phase 1/2 multicenter clinical trialWALTHAM, Mass.--(BUSINESS WIRE)--#NRTK--Pyramid Biosciences, Inc., a clinical-stage biotechnology compan...

/PRNewswire/ -- Pyramid Biosciences, Inc., and Caris Life Sciences® (Caris), today announced a collaboration to enhance identification of potential patients...

/PRNewswire/ -- Pyramid Biosciences, Inc., and Caris Life Sciences® (Caris), today announced a collaboration to enhance identification of potential patients...

Pyramid Biosciences Appoints Brian Lestini, MD, PhD as Chief Executive Officer - read this article along with other careers information, tips and advice on BioSpace

Published: Apr 14, 2021   Jeffrey Wasserman, JD, named General Counsel   WALTHAM, Mass.--(BUSINESS WIRE)-- Pyramid Biosciences, Inc., a Boston-based, clinical-stage biotechnology company focused on developing new and highly differentiated precision therapies for cancer and other serious diseases, today announced two new appointments to the leadership team. Brian Lestini, MD, PhD, has joined the company as Chief Medical Officer, where he will oversee the advancement and expansion of the Co...